FDA
-
-
-
-
-
-
-
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
-
-
-
-
-
-
Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
-
-
-
-
-
-
-
Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference
-
-
-
-
-
-
-
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
-
-
-
-
-
-
-
Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
Cytokinetics (CYTK) PT Raised to $95 at RBC Capital
-
-
-
-
-
-
-
Cytokinetics receives China approval for heart drug MYQORZO
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

